Colchicine derivative as a potential anti-glioma compound

Kuan Min Fang, Jun Jen Liu, Chun Chun Li, Chih Chi Cheng, Yun Ti Hsieh, Kit Man Chai, Yu An Lien, Shun Fen Tzeng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Colchicine, an anti-microtubule and antimitotic drug, is a common therapeutically agent for gout, which is thought to have potential anti-tumor effects. Owing to concerns of colchicines poisoning, the development of derivatives with low dose efficacy and less side effects is of obvious interest. In this study, we characterized the inhibitory effects of a colchicine derivative named AD1 on the cell proliferation of human malignant glioblastoma (MG) cell lines, U87MG and U373MG. We found that 50 % of U87MG and U373MG cells were reduced in the cultures after exposure to AD1 for 24 h at 10 and 50 nM, respectively. Moreover, α-tubulin immunostaining indicated that AD1 induced the disruption of the microtubule polymerization in glioma cells with apoptotic features including membrane budding/blebbing or fragmented nuclei. Increased levels of reactive oxygen species (ROS) were also detected in AD1-treated U87MG and U373MG cells compared to that observed in the control culture. Moreover, examination of microtubule-associated protein 1A/1B-light chain 3 (LC3I)/LC3II conversion and acridine orange staining for autophagic vesicles, combined with flow cytometry, showed that treatment with AD1 induced the autophagic pathway in U87MG and U373MG cells. Furthermore, we found that the intermittent intravenous administration of AD1 suppressed glioma growth in rat brain receiving intracerebral injection with rat C6 glioma cells. Taken together, our findings reveal that treatment with AD1 at nanomolar scales can reduce glioma cell viability effectively, with the occurrence of a rise in ROS and cellular autophagy. In conjunction with the observations from in vivo study, the colchicine derivative AD1 has chemotherapeutic potential to suppress glioma progression.

Original languageEnglish
Pages (from-to)403-412
Number of pages10
JournalJournal of Neuro-Oncology
Volume124
Issue number3
DOIs
Publication statusPublished - Aug 4 2015

Fingerprint

Colchicine
Glioma
Microtubules
Reactive Oxygen Species
Antimitotic Agents
Acridine Orange
Gout
Autophagy
Blister
Tubulin
Glioblastoma
Polymerization
Intravenous Administration
Poisoning
Cell Survival
Flow Cytometry
Cell Proliferation
Staining and Labeling
Light
Cell Line

Keywords

  • Acidic vesicular organelles
  • AD1
  • Autophagy
  • Colchicine
  • Glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Fang, K. M., Liu, J. J., Li, C. C., Cheng, C. C., Hsieh, Y. T., Chai, K. M., ... Tzeng, S. F. (2015). Colchicine derivative as a potential anti-glioma compound. Journal of Neuro-Oncology, 124(3), 403-412. https://doi.org/10.1007/s11060-015-1874-2

Colchicine derivative as a potential anti-glioma compound. / Fang, Kuan Min; Liu, Jun Jen; Li, Chun Chun; Cheng, Chih Chi; Hsieh, Yun Ti; Chai, Kit Man; Lien, Yu An; Tzeng, Shun Fen.

In: Journal of Neuro-Oncology, Vol. 124, No. 3, 04.08.2015, p. 403-412.

Research output: Contribution to journalArticle

Fang, KM, Liu, JJ, Li, CC, Cheng, CC, Hsieh, YT, Chai, KM, Lien, YA & Tzeng, SF 2015, 'Colchicine derivative as a potential anti-glioma compound', Journal of Neuro-Oncology, vol. 124, no. 3, pp. 403-412. https://doi.org/10.1007/s11060-015-1874-2
Fang, Kuan Min ; Liu, Jun Jen ; Li, Chun Chun ; Cheng, Chih Chi ; Hsieh, Yun Ti ; Chai, Kit Man ; Lien, Yu An ; Tzeng, Shun Fen. / Colchicine derivative as a potential anti-glioma compound. In: Journal of Neuro-Oncology. 2015 ; Vol. 124, No. 3. pp. 403-412.
@article{58c12ff4bb6346fcaca81e52c77d1f67,
title = "Colchicine derivative as a potential anti-glioma compound",
abstract = "Colchicine, an anti-microtubule and antimitotic drug, is a common therapeutically agent for gout, which is thought to have potential anti-tumor effects. Owing to concerns of colchicines poisoning, the development of derivatives with low dose efficacy and less side effects is of obvious interest. In this study, we characterized the inhibitory effects of a colchicine derivative named AD1 on the cell proliferation of human malignant glioblastoma (MG) cell lines, U87MG and U373MG. We found that 50 {\%} of U87MG and U373MG cells were reduced in the cultures after exposure to AD1 for 24 h at 10 and 50 nM, respectively. Moreover, α-tubulin immunostaining indicated that AD1 induced the disruption of the microtubule polymerization in glioma cells with apoptotic features including membrane budding/blebbing or fragmented nuclei. Increased levels of reactive oxygen species (ROS) were also detected in AD1-treated U87MG and U373MG cells compared to that observed in the control culture. Moreover, examination of microtubule-associated protein 1A/1B-light chain 3 (LC3I)/LC3II conversion and acridine orange staining for autophagic vesicles, combined with flow cytometry, showed that treatment with AD1 induced the autophagic pathway in U87MG and U373MG cells. Furthermore, we found that the intermittent intravenous administration of AD1 suppressed glioma growth in rat brain receiving intracerebral injection with rat C6 glioma cells. Taken together, our findings reveal that treatment with AD1 at nanomolar scales can reduce glioma cell viability effectively, with the occurrence of a rise in ROS and cellular autophagy. In conjunction with the observations from in vivo study, the colchicine derivative AD1 has chemotherapeutic potential to suppress glioma progression.",
keywords = "Acidic vesicular organelles, AD1, Autophagy, Colchicine, Glioma",
author = "Fang, {Kuan Min} and Liu, {Jun Jen} and Li, {Chun Chun} and Cheng, {Chih Chi} and Hsieh, {Yun Ti} and Chai, {Kit Man} and Lien, {Yu An} and Tzeng, {Shun Fen}",
year = "2015",
month = "8",
day = "4",
doi = "10.1007/s11060-015-1874-2",
language = "English",
volume = "124",
pages = "403--412",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Colchicine derivative as a potential anti-glioma compound

AU - Fang, Kuan Min

AU - Liu, Jun Jen

AU - Li, Chun Chun

AU - Cheng, Chih Chi

AU - Hsieh, Yun Ti

AU - Chai, Kit Man

AU - Lien, Yu An

AU - Tzeng, Shun Fen

PY - 2015/8/4

Y1 - 2015/8/4

N2 - Colchicine, an anti-microtubule and antimitotic drug, is a common therapeutically agent for gout, which is thought to have potential anti-tumor effects. Owing to concerns of colchicines poisoning, the development of derivatives with low dose efficacy and less side effects is of obvious interest. In this study, we characterized the inhibitory effects of a colchicine derivative named AD1 on the cell proliferation of human malignant glioblastoma (MG) cell lines, U87MG and U373MG. We found that 50 % of U87MG and U373MG cells were reduced in the cultures after exposure to AD1 for 24 h at 10 and 50 nM, respectively. Moreover, α-tubulin immunostaining indicated that AD1 induced the disruption of the microtubule polymerization in glioma cells with apoptotic features including membrane budding/blebbing or fragmented nuclei. Increased levels of reactive oxygen species (ROS) were also detected in AD1-treated U87MG and U373MG cells compared to that observed in the control culture. Moreover, examination of microtubule-associated protein 1A/1B-light chain 3 (LC3I)/LC3II conversion and acridine orange staining for autophagic vesicles, combined with flow cytometry, showed that treatment with AD1 induced the autophagic pathway in U87MG and U373MG cells. Furthermore, we found that the intermittent intravenous administration of AD1 suppressed glioma growth in rat brain receiving intracerebral injection with rat C6 glioma cells. Taken together, our findings reveal that treatment with AD1 at nanomolar scales can reduce glioma cell viability effectively, with the occurrence of a rise in ROS and cellular autophagy. In conjunction with the observations from in vivo study, the colchicine derivative AD1 has chemotherapeutic potential to suppress glioma progression.

AB - Colchicine, an anti-microtubule and antimitotic drug, is a common therapeutically agent for gout, which is thought to have potential anti-tumor effects. Owing to concerns of colchicines poisoning, the development of derivatives with low dose efficacy and less side effects is of obvious interest. In this study, we characterized the inhibitory effects of a colchicine derivative named AD1 on the cell proliferation of human malignant glioblastoma (MG) cell lines, U87MG and U373MG. We found that 50 % of U87MG and U373MG cells were reduced in the cultures after exposure to AD1 for 24 h at 10 and 50 nM, respectively. Moreover, α-tubulin immunostaining indicated that AD1 induced the disruption of the microtubule polymerization in glioma cells with apoptotic features including membrane budding/blebbing or fragmented nuclei. Increased levels of reactive oxygen species (ROS) were also detected in AD1-treated U87MG and U373MG cells compared to that observed in the control culture. Moreover, examination of microtubule-associated protein 1A/1B-light chain 3 (LC3I)/LC3II conversion and acridine orange staining for autophagic vesicles, combined with flow cytometry, showed that treatment with AD1 induced the autophagic pathway in U87MG and U373MG cells. Furthermore, we found that the intermittent intravenous administration of AD1 suppressed glioma growth in rat brain receiving intracerebral injection with rat C6 glioma cells. Taken together, our findings reveal that treatment with AD1 at nanomolar scales can reduce glioma cell viability effectively, with the occurrence of a rise in ROS and cellular autophagy. In conjunction with the observations from in vivo study, the colchicine derivative AD1 has chemotherapeutic potential to suppress glioma progression.

KW - Acidic vesicular organelles

KW - AD1

KW - Autophagy

KW - Colchicine

KW - Glioma

UR - http://www.scopus.com/inward/record.url?scp=84942502654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942502654&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1874-2

DO - 10.1007/s11060-015-1874-2

M3 - Article

C2 - 26239968

AN - SCOPUS:84942502654

VL - 124

SP - 403

EP - 412

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -